ClinChoice, a Sino-US contract research organisation (CRO), has raised $150 million in as Series E funding round led by Legend Capital, the fund management arm of Chinese conglomerate Legend Holdings, according to a report by DealStreetAsia.
The round also tracked new support from Beijing-based life insurance company Taikang Life Insurance and healthcare investment firm Sherpa Healthcare Partners, as well as existing investors Lilly Asia Ventures and Apricot Capital.
ClinChoice, which was founded by Xin Ke, a pharmaceutical industry veteran who specialises in data management and statistical programming, and John D Balian, who previously founded consulting firm MediVista before his tenures at companies including Johnson & Johnson and Pfizer, has previously been backed by Goldman Sachs and DFJ Dragon Fund.
ClinChoice provides integrated clinical development services to pharmaceutical, biotech, medical device, and consumer health clients in the US, China, Europe, and Southeast Asia.
